Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01149395 · ClinicalTrials.gov registry record · Phase 1

Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn

A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT01149395 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01149395, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

The purpose of this research study is to determine in heartburn patients with nonerosive disease if detecting the presence of a fragment of the protein e-cadherin in esophageal epithelium or the amount of fragments of e-cadherin in blood can be used to monitor healing of esophagitis treated with a proton pump inhibitor (PPI). The hypothesis is that the presence of fragments of e-cadherin in esophageal epithelium or the amount of fragments of e-cadherin in blood can you useful as a biomarker for the healing of esophagitis in patients successfully treated with a PPI.

Interventions

  • DRUG Dexlansoprazole

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2010-06
Est. Completion 2012-04
Phase Phase 1

What the Registry Record Tells You About NCT01149395

The ClinicalTrials.gov registry entry for NCT01149395 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Dexlansoprazole is the first listed.

NCT01149395 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01149395 about?

NCT01149395 is a clinical study titled "Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn". The purpose of this research study is to determine in heartburn patients with nonerosive disease if detecting the presence of a fragment of the protein e-cadherin in esophageal epithelium or the amount of fragments of e-cadherin in blood can be used to monitor healing of esophagitis treated with a p...

What is the current status of trial NCT01149395?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2010-06. Estimated completion is 2012-04.

What interventions are being tested in trial NCT01149395?

The interventions under investigation include: Dexlansoprazole (DRUG).

Who is sponsoring clinical trial NCT01149395?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.